/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/hem---leukemia/,

/clinical/cckm-tools/content/beacon-protocols/hem---leukemia/name-96842-en.cckm

201611333

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Hem - Leukemia

CSC HEM ALL CALGB 10403 Extended Remission Induction(15D) VER 11-21-16 (HL 5802)

CSC HEM ALL CALGB 10403 Extended Remission Induction(15D) VER 11-21-16 (HL 5802) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Hem - Leukemia


CSC HEM ALL CALGB 10403 EXTENDED REMISSION INDUCTION(15D) VER: 11-21-16 – Properties
Pre-Cycle – 11/21/2016 through 11/27/2016 (7 days), Planned
Day 1, Pre-Cycle – Planned for 11/21/2016
Treatment Plan Information
Treatment Plan Summary
Disease: Acute Lymphoblastic Leukemia; EXTENDED REMISSION INDUCTION THERAPY: prednisone 30 mg/m2 by mouth twice
daily Days 1 through 14, DAUNOrubicin 25 mg/m2 IV Day 1, vinCRIStine 1.5 mg/m2 (max dose = 2 mg) IV Day 1 and 8,
pegaspargase 2500 units/m2 IM Day 4 (or Day 5 or Day 6); CYCLE LENGTH: 15 days; COURSE: 1 cycle, followed by
Consolidation.
Note to All Staff (1)
Chemotherapy Council approved for patients less than 40 years of age.
Note to All Staff (2)
Intended ONLY FOR PATIENTS WITH DAY I-29 M2 MARROW (greater than 5% lymphoblasts) or Day I-29 M1 marrow with greater
than or equal to 1% lymphoblasts. Patients meeting these criteria are to begin Extended Remission Induction therapy as soon as
possible after Induction and ideally on Day 30.
Consent
Verify Consent
Verify informed consent has been obtained.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S Approximate, Expires-S+365, Routine
BUN
Expected-S Approximate, Expires-S+365, Routine
CREATININE
Expected-S Approximate, Expires-S+365, Routine
CALCIUM
Expected-S Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S Approximate, Expires-S+365, Normal, Routine
AST/SGOT
Expected-S Approximate, Expires-S+365, Normal, Routine
ALT/SGPT
Expected-S Approximate, Expires-S+365, Normal, Routine
ALKALINE PHOSPHATASE
Expected-S Approximate, Expires-S+365, Routine
LD, TOTAL
Expected-S Approximate, Expires-S+365, Routine
PHOSPHATE
Expected-S Approximate, Expires-S+365, Routine
URIC ACID
Expected-S Approximate, Expires-S+365, Routine
AMYLASE
Expected-S Approximate, Expires-S+365, Routine
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 1 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

LIPASE
Expected-S Approximate, Expires-S+365, Routine
FIBRINOGEN
Expected-S Approximate, Expires-S+365, Routine
PROTHROMBIN TIME/INR
Expected-S Approximate, Expires-S+365, Routine
PTT
Expected-S Approximate, Expires-S+365, Routine
Take Home Medications
sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tab
Take 1 tablet by mouth twice daily on Saturday and Sunday., Disp-16 tab, R-11, starting S, Local Printer
acyclovir (ZOVIRAX) 400 MG tab
Take 1 tab by mouth 2 times daily., 400 mg, Disp-60 tab, R-11, 2 X DAILY starting S, Local Printer
fluconazole (DIFLUCAN) 200 MG tab
Take 2 tabs by mouth one time daily., 400 mg, Disp-60 tab, R-11, 1 X DAILY starting S, Local Printer
ranitidine (ZANTAC) 150 MG tab
Take 1 tab by mouth 2 times daily., 150 mg, Disp-60 tab, R-11, 2 X DAILY starting S, Local Printer
epINEPHrine (EPIPEN) 0.3 MG/0.3ML soln auto-injector
Give 0.3 mg intramuscularly as needed. Remind patient to bring to clinic., 0.3 mg, R-0, PRN starting S
diphenhydramine (BENADRYL) 25 MG cap
Take 1 cap by mouth every 6 hours as needed for itching (For allergic reaction.). Available over-the-counter., 25 mg, Disp-30
cap, R-1, EVERY 6 HOURS PRN starting S
Take Home Medications (delete all that do not apply)
levofloxacin (LEVAQUIN) 500 MG tab
Take 1 tablet by mouth once daily starting on Day *** until ANC greater than *** after nadir., Disp-14 tab, R-0, starting S, Local
Printer
Cycle 1 Extended Remission Induction – 11/28/2016 through 12/12/2016 (15 days), Planned
Day 1, Cycle 1 Extended Remission Induction – Planned for 11/28/2016
Treatment Plan Information
Reference Information (1)
ACUTE LYMPHOBLASTIC LEUKEMIA: Stock W, et al. Blood 2014;124(21):796.
Reference Information (2)
ACUTE LYMPHOBLASTIC LEUKEMIA: Advani A, et al. Blood 2013;122(21):3903.
Reference Information (3)
ACUTE LYMPHOBLASTIC LEUKEMIA: National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia (version 2.2014).
http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed June 9, 2015.
Treatment Plan Summary
Disease: Acute Lymphoblastic Leukemia; EXTENDED REMISSION INDUCTION THERAPY: prednisone 30 mg/m2 by mouth twice
daily Days 1 through 14, DAUNOrubicin 25 mg/m2 IV Day 1, vinCRIStine 1.5 mg/m2 (max dose = 2 mg) IV Day 1 and 8,
pegaspargase 2500 units/m2 IM Day 4 (or Day 5 or Day 6); CYCLE LENGTH: 15 days; COURSE: 1 cycle, followed by
Consolidation.
Note to All Staff (1)
Chemotherapy Council approved for patients less than 40 years of age.
Note to All Staff (2)
Intended ONLY FOR PATIENTS WITH DAY I-29 M2 MARROW (greater than 5% lymphoblasts) or Day I-29 M1 marrow with greater
than or equal to 1% lymphoblasts. Patients meeting these criteria are to begin Extended Remission Induction therapy as soon as
possible after Induction and ideally on Day 30.
Consent
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 2 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

Verify Consent
Verify informed consent has been obtained.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Treatment Conditions
Verify Labs
Verify the following labs have been obtained: Total Bilirubin.
Treatment Parameters
Hold and notify authorizing provider for: Total Bilirubin greater than or equal to ULN.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Pre-Medications
NOTE:
ONCE, 1 dose Starting when released
Patient should not receive additional steroids for antiemetic therapy.
ondansetron (ZOFRAN) tab 16 mg
16 mg, Oral, ONCE, 1 dose Starting when released
Give prior to chemotherapy.
Treatment Medications
prednisone (DELTASONE) tab 59 mg
59 mg (rounded from 58.8 mg = 30 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Oral, ONCE, 1 dose Starting
when released
Do not taper.
DAUNOrubicin (CERUBIDINE) injection 49 mg
49 mg (25 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose Starting when released,
Administer over 15 Minutes
Administer IV push into rapid running IV. Administer over 15 minutes.
vinCRIStine (ONCOVIN) 2.9 mg in sodium chloride 0.9 % 25 mL bag
2.9 mg (rounded from 2.94 mg = 1.5 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose
Starting when released
Administer over 5 minutes. Max dose = 2 mg.
Take Home Medications (delete all that do not apply)
prednisone (DELTASONE) 10 MG tab
Ordered dose of 1.5 mg/m2 ONCE exceeds the recommended single dose limit of 2 mg.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 3 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

Take 6 tabs by mouth 2 times daily at mealtime. Take on Day 1 through 14., 60 mg (rounded from 58.8 mg = 30 mg/m2 × 1.96
m2 Treatment plan BSA from recorded weight), 2 X DAILY (AT MEALTIME) starting S, Local Printer
Do not taper.
prednisone (DELTASONE) 20 MG tab
Take 3 tabs by mouth 2 times daily at mealtime. Take on Day 1 through 14., 60 mg (rounded from 58.8 mg = 30 mg/m2 × 1.96
m2 Treatment plan BSA from recorded weight), 2 X DAILY (AT MEALTIME) starting S, Local Printer
Do not taper.
prednisone (DELTASONE) 50 MG tab
Take 1 tab by mouth 2 times daily at mealtime. Take on Day 1 through 14. Do not taper., 50 mg (rounded from 58.8 mg = 30
mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), R-0, 2 X DAILY (AT MEALTIME) starting S, Local Printer
Follow-Up
DAY 4 FOLLOW-UP
CHEMOTHERAPY ROOM APPOINTMENT: pegaspargase for 90 minutes.
DAY 8 FOLLOW-UP
RETURN TO CLINIC for appointment with provider; LABS: CBC with DIFF, Electrolytes, Glucose, BUN, Creatinine, Calcium,
Phosphate, Uric Acid, Total Bilirubin, AST, ALT, Alkaline Phosphatase, Total LD, Amylase, Lipase, Fibrinogen, PT/INR, and PTT;
CHEMOTHERAPY ROOM APPOINTMENT: vinCRIStine for 30 minutes.
DAY 11 FOLLOW-UP
LABS: Fibrinogen, PT/INR, and PTT.
DAY 16 FOLLOW-UP
(Day 1 of Consolidation) RETURN TO CLINIC for appointment with provider. LABS: CBC with DIFF, Electrolytes, Glucose, BUN,
Creatinine, Calcium, Total LD, Phosphate, Uric Acid, Total Bilirubin, AST, ALT, Alkaline Phosphatase; CHEMOTHERAPY ROOM
APPOINTMENT: cyclophosphamide, cytarabine, IT methotrexate for 120 minutes.
Day 4, Cycle 1 Extended Remission Induction – Planned for 12/1/2016
Treatment Plan Information
Treatment Plan Summary
Disease: Acute Lymphoblastic Leukemia; EXTENDED REMISSION INDUCTION THERAPY: prednisone 30 mg/m2 by mouth twice
daily Days 1 through 14, DAUNOrubicin 25 mg/m2 IV Day 1, vinCRIStine 1.5 mg/m2 (max dose = 2 mg) IV Day 1 and 8,
pegaspargase 2500 units/m2 IM Day 4 (or Day 5 or Day 6); CYCLE LENGTH: 15 days; COURSE: 1 cycle, followed by
Consolidation.
Note to All Staff (1)
Chemotherapy Council approved for patients less than 40 years of age.
Note to All Staff (2)
Intended ONLY FOR PATIENTS WITH DAY I-29 M2 MARROW (greater than 5% lymphoblasts) or Day I-29 M1 marrow with greater
than or equal to 1% lymphoblasts. Patients meeting these criteria are to begin Extended Remission Induction therapy as soon as
possible after Induction and ideally on Day 30.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Treatment Conditions
Verify Medication(s) Taken at Home (1)
Verify that patient has taken prednisone and document in a progress note. Notify authorizing prescriber if patient has not taken
medication as prescribed.
Nursing Procedure, Assessment and Monitoring
Hypersensitivity Monitoring (1)
Hypersensitivity to pegaspargase can occur and may be immediate or not appear for hours after drug administration. See vital signs
and emergency medications. Patient should have Epipen and oral diphenhydramine (Benadryl) available for home use.
Vital Signs
30 mg/m2 (58.8 mg = 1.176 tab) cannot be prescribed using the selected product.
The nearest available dose is 50 mg (25.5 mg/m2).
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 4 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

SEE COMMENTS Starting when released Until Specified
Check blood pressure, heart rate, and respiratory rate 15 minutes before pegaspargase administration and for 1 hour post-
administration.
Patient Instructions(1)
Verify patient has Epipen to use in clinic for emergency needs.
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Pre-Medications
NOTE:
ONCE, 1 dose Starting when released
Patient should not receive additional steroids for antiemetic therapy.
acetaMINOPHEN (TYLENOL) tab 650 mg
650 mg, Oral, ONCE, 1 dose Starting when released
Administer prior to pegaspargase.
diphenhydramine (BENADRYL) cap 25 mg
25 mg, Oral, ONCE, 1 dose Starting when released
Administer prior to pegaspargase.
Emergency Medications
diphenhydramine (BENADRYL) injection 25 mg
25 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction, Administer over 1 Minutes
diphenhydramine (BENADRYL) injection 50 mg
50 mg, Intravenous, PRN, 1 dose Starting when released, infusion reaction, Administer over 1 Minutes
albuterol 2.5 mg/3 mL neb soln
2.5 mg, Nebulization, PRN, 1 dose Starting when released, infusion reaction
Treatment Medications
NOTE:
ONCE, 1 dose Starting when released
Intramuscular route preferred for pegaspargase due to increased incidence of allergic reaction with intravenous route in adults.
pegaspargase (ONCASPAR) injection 4,897.5 units
4,897.5 units (rounded from 4,900 units = 2,500 Units/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intramuscular,
ONCE, 1 dose Starting when released
Hypersensitivity to pegaspargase can occur and may be immediate or not appear for hours after drug administration. See Vital Signs
and Emergency Medications. There is a 1 hour observation and vital signs period post injection.
See Take Home Medication(s)
Refer to the take home medication section for the following treatment medication(s): prednisone (dispensed on Day 1)
Take Home Medications
diphenhydramine (BENADRYL) 25 MG cap
Take 1 cap by mouth every 6 hours as needed for itching (For allergic reaction.). Available over-the-counter., 25 mg, Disp-30
cap, R-1, EVERY 6 HOURS PRN starting S
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 5 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

epINEPHrine (EPIPEN) 0.3 MG/0.3ML soln auto-injector
Give 0.3 mg intramuscularly as needed. Remind patient to bring to clinic., 0.3 mg, R-0, PRN starting S
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Day 8, Cycle 1 Extended Remission Induction – Planned for 12/5/2016
Treatment Plan Information
Treatment Plan Summary
Disease: Acute Lymphoblastic Leukemia; EXTENDED REMISSION INDUCTION THERAPY: prednisone 30 mg/m2 by mouth twice
daily Days 1 through 14, DAUNOrubicin 25 mg/m2 IV Day 1, vinCRIStine 1.5 mg/m2 (max dose = 2 mg) IV Day 1 and 8,
pegaspargase 2500 units/m2 IM Day 4 (or Day 5 or Day 6); CYCLE LENGTH: 15 days; COURSE: 1 cycle, followed by
Consolidation.
Note to All Staff (1)
Chemotherapy Council approved for patients less than 40 years of age.
Note to All Staff (2)
Intended ONLY FOR PATIENTS WITH DAY I-29 M2 MARROW (greater than 5% lymphoblasts) or Day I-29 M1 marrow with greater
than or equal to 1% lymphoblasts. Patients meeting these criteria are to begin Extended Remission Induction therapy as soon as
possible after Induction and ideally on Day 30.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
CBC WITH DIFFERENTIAL
Expected-S+4 Approximate, Expires-S+365, Routine
ELECTROLYTES
Expected-S+4 Approximate, Expires-S+365, Routine
GLUCOSE
Expected-S+4 Approximate, Expires-S+365, Routine
BUN
Expected-S+4 Approximate, Expires-S+365, Routine
CREATININE
Expected-S+4 Approximate, Expires-S+365, Routine
CALCIUM
Expected-S+4 Approximate, Expires-S+365, Routine
BILIRUBIN, TOTAL
Expected-S+4 Approximate, Expires-S+365, Normal, Routine
AST/SGOT
Expected-S+4 Approximate, Expires-S+365, Normal, Routine
ALT/SGPT
Expected-S+4 Approximate, Expires-S+365, Normal, Routine
ALKALINE PHOSPHATASE
Expected-S+4 Approximate, Expires-S+365, Routine
LD, TOTAL
Expected-S+4 Approximate, Expires-S+365, Routine
PHOSPHATE
Expected-S+4 Approximate, Expires-S+365, Routine
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 6 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

URIC ACID
Expected-S+4 Approximate, Expires-S+365, Routine
AMYLASE
Expected-S+4 Approximate, Expires-S+365, Routine
LIPASE
Expected-S+4 Approximate, Expires-S+365, Routine
FIBRINOGEN
Expected-S+4 Approximate, Expires-S+365, Routine
PROTHROMBIN TIME/INR
Expected-S+4 Approximate, Expires-S+365, Routine
PTT
Expected-S+4 Approximate, Expires-S+365, Routine
Treatment Conditions
Verify Medication(s) Taken at Home (1)
Verify that patient has taken prednisone and document in a progress note. Notify authorizing prescriber if patient has not taken
medication as prescribed.
Nursing Procedure, Assessment and Monitoring
Flush Venous Access Device per Guidelines
Order details
sodium chloride flush 0.9% 10 mL injection
Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin lock flush 10 UNIT/ML injection 1-150 units
1-150 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Flush per VAD guidelines.
heparin 100 UNIT/ML lock flush injection 500 units
500 units, Flush, PRN Starting when released Until Discontinued, flush/line care
Implanted port use ONLY to be used when de-accessing port. Flush per VAD guidelines.
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Treatment Medications
vinCRIStine (ONCOVIN) 2.9 mg in sodium chloride 0.9 % 25 mL bag
2.9 mg (rounded from 2.94 mg = 1.5 mg/m2 × 1.96 m2 Treatment plan BSA from recorded weight), Intravenous, ONCE, 1 dose
Starting when released
Administer over 5 minutes. Max dose = 2 mg.
See Take Home Medication(s)
Refer to the take home medication section for the following treatment medication(s): prednisone (dispensed on Day 1).
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Lab Only - Day 11, Cycle 1 Extended Remission Induction – Planned for 12/8/2016
Treatment Plan Information
Treatment Plan Summary
Disease: Acute Lymphoblastic Leukemia; EXTENDED REMISSION INDUCTION THERAPY: prednisone 30 mg/m2 by mouth twice
daily Days 1 through 14, DAUNOrubicin 25 mg/m2 IV Day 1, vinCRIStine 1.5 mg/m2 (max dose = 2 mg) IV Day 1 and 8,
Ordered dose of 1.5 mg/m2 ONCE exceeds the recommended single dose limit of 2 mg.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 7 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org

pegaspargase 2500 units/m2 IM Day 4 (or Day 5 or Day 6); CYCLE LENGTH: 15 days; COURSE: 1 cycle, followed by
Consolidation.
Note to All Staff (1)
Chemotherapy Council approved for patients less than 40 years of age.
Note to All Staff (2)
Intended ONLY FOR PATIENTS WITH DAY I-29 M2 MARROW (greater than 5% lymphoblasts) or Day I-29 M1 marrow with greater
than or equal to 1% lymphoblasts. Patients meeting these criteria are to begin Extended Remission Induction therapy as soon as
possible after Induction and ideally on Day 30.
IV Access
Insert and Maintain Peripheral IV
CONTINUOUS Starting when released Until Specified
Peripheral IV Size: RN Discretion
Additional PIV may be inserted as needed for repeat blood sampling or IV medication administration.
Pre-Labs
FIBRINOGEN
Expected-S+3 Approximate, Expires-S+122, Normal, Routine
PROTHROMBIN TIME/INR
Expected-S+3 Approximate, Expires-S+397, Normal, Routine
PTT
Expected-S+3 Approximate, Expires-S+122, Normal, Routine
Follow-Up
VERIFY APPOINTMENTS
Verify next day appointment(s) have been scheduled. See follow-up section on Day 1.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Zztestonc,Jeff J [2507481]
11/21/2016 8:34:59 AM Page 8 of 8
Copyright © 201� University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2016CCKM@uwhealth.org